- Home
- GILD vs COF Comparison
GILD vs COF Comparison
Compare GILD & COF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GILD
- COF
- Stock Information
- Founded
- GILD 1987
- COF 1988
- Country
- GILD United States
- COF United States
- Employees
- GILD N/A
- COF N/A
- Industry
- GILD Biotechnology: Biological Products (No Diagnostic Substances)
- COF Major Banks
- Sector
- GILD Health Care
- COF Finance
- Exchange
- GILD Nasdaq
- COF Nasdaq
- Market Cap
- GILD 139.6B
- COF 144.9B
- IPO Year
- GILD 1992
- COF 1994
- Fundamental
- Price
- GILD $113.62
- COF $229.74
- Analyst Decision
- GILD Buy
- COF Buy
- Analyst Count
- GILD 23
- COF 15
- Target Price
- GILD $116.36
- COF $237.40
- AVG Volume (30 Days)
- GILD 5.9M
- COF 2.9M
- Earning Date
- GILD 11-05-2025
- COF 10-23-2025
- Dividend Yield
- GILD 2.78%
- COF 1.04%
- EPS Growth
- GILD 496.80
- COF N/A
- EPS
- GILD 5.01
- COF N/A
- Revenue
- GILD $28,863,000,000.00
- COF $23,773,000,000.00
- Revenue This Year
- GILD $2.07
- COF $94.57
- Revenue Next Year
- GILD $3.95
- COF $18.32
- P/E Ratio
- GILD $22.69
- COF N/A
- Revenue Growth
- GILD 3.81
- COF N/A
- 52 Week Low
- GILD $81.83
- COF $143.22
- 52 Week High
- GILD $121.83
- COF $232.45
- Technical
- Relative Strength Index (RSI)
- GILD 48.34
- COF 62.70
- Support Level
- GILD $110.15
- COF $222.32
- Resistance Level
- GILD $114.13
- COF $230.50
- Average True Range (ATR)
- GILD 2.28
- COF 4.87
- MACD
- GILD -0.31
- COF 0.17
- Stochastic Oscillator
- GILD 43.59
- COF 93.84
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
About COF Capital One Financial Corporation
Capital One is a diversified financial services holding company headquartered in McLean, Virginia. Originally a spinoff of Signet Financial's credit card division in 1994, the company is now primarily involved in credit card lending, auto loans, and commercial lending. Following the acquisition of Discover in 2025, the firm also has a modest personal loan business, though credit card lending still provides the majority of the bank's revenue.